[HTML][HTML] The impact of VEGF on cancer metastasis and systemic disease

Y Yang, Y Cao - Seminars in cancer biology, 2022 - Elsevier
Metastasis is the leading cause of cancer-associated mortality and the underlying
mechanisms of cancer metastasis remain elusive. Both blood and lymphatic vasculatures …

Gastrointestinal stromal tumours

JY Blay, YK Kang, T Nishida… - Nature reviews Disease …, 2021 - nature.com
Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

[HTML][HTML] Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer… - Annals of oncology, 2022 - Elsevier
Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

[HTML][HTML] Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

L Huang, S Jiang, Y Shi - Journal of hematology & oncology, 2020 - Springer
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

[HTML][HTML] Tumor angiogenesis: causes, consequences, challenges and opportunities

R Lugano, M Ramachandran, A Dimberg - Cellular and Molecular Life …, 2020 - Springer
Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

Challenges and opportunities in cancer drug resistance

RA Ward, S Fawell, N Floc'h, V Flemington… - Chemical …, 2020 - ACS Publications
There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

MC Heinrich, RL Jones, M von Mehren… - The Lancet …, 2020 - thelancet.com
Background Targeting of KIT and PDGFRA with imatinib revolutionised treatment in
gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated …

[HTML][HTML] The management of metastatic GIST: current standard and investigational therapeutics

CM Kelly, L Gutierrez Sainz, P Chi - Journal of Hematology & Oncology, 2021 - Springer
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …

[HTML][HTML] The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF

S Ghalehbandi, J Yuzugulen, MZI Pranjol… - European Journal of …, 2023 - Elsevier
Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …

[HTML][HTML] The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy

F Ardito, M Giuliani, D Perrone… - International …, 2017 - spandidos-publications.com
Protein phosphorylation is an important cellular regulatory mechanism as many enzymes
and receptors are activated/deactivated by phosphorylation and dephosphorylation events …